baxter travenol laboratories said its hyland therapeutics unit has started first human clinical trials genetically engineered factor viii clotting agent missing from blood most hemophiliacs said unlike factor viii concentrates currently genetically engineered factor viii would not limited availability human plasma and will completely free from blood borne viruses including aids and all forms hepatitis baxter said baxter also said final states clinical trials highly purified form factor viii derived from human plasma produced using advanced process incorporating monoclonal antibody purification said genetics institute publicly held biotechnology company which baxter shareholder will supply protein used for human clinical testing well substantial portion ongoing production requirements reuter 